logo
Share SHARE
FONT-SIZE Plus   Neg

4SC Says Its Resminostat Meets Primary Endpoint In Phase II Trial

4SC AG (FSCGF.PK) published encouraging efficacy data from the clinical Phase II SHELTER study with the cancer drug resminostat as a second-line therapy for patients with advanced liver cancer (hepatocellular carcinoma, HCC) who had exhibited radiologically proven tumour progression under first-line therapy with sorafenib prior to study entry.

The open-label, two-arm, international study investigated the safety and efficacy of resminostat both as a monotherapy and in combination with sorafenib for difficult to treat patient group, for which no approved treatment option is currently available.

According to the data now presented, which is based on an advanced data set, the primary study endpoint of halting the further progression of the particularly aggressive cancer in at least 20% of the patients treated and for at least 12 weeks has been achieved ahead of schedule in both therapy arms.

In general, resminostat has proven to be safe and well-tolerated. The most frequent side-effects observed were of a gastrointestinal nature.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Sanofi SA were gaining around 2 percent in the early morning trading in Paris after the French drug giant reported significantly higher profit in its first quarter, benefited by 4.4 billion euros gains from the disposal of its Merial animal healthcare unit and higher sales. For fiscal 2017, Sanofi said it continues to expect Business earnings per share to be stable to negative 3 percent. Shares of UBS Group AG were gaining around 4 percent in the early morning trading after the Swiss banking giant reported Friday significantly higher profit in its first quarter, despite weakness in net interest income. The company also proposed a dividend. Looking ahead, UBS said it is well positioned to mitigate various market challenges... Alphabet Inc. (GOOG, GOOGL), the parent company of Google, Thursday reported an increase in profit for the first quarter, driven largely revenue growth in search and advertising. Alphabet's first-quarter profit rose to $5.43 billion or $7.73 per share from $4.21 billion or $6.02 per share last year. On...
comments powered by Disqus
Follow RTT